Anticoagulation for Atrial Fibrillation

Introduction to Anticoagulation Guidelines

The American Heart Association and American College of Cardiology recommend therapeutic anticoagulation for patients with atrial fibrillation and stroke risk factors (CHA₂DS₂-VASc score ≥2 in men or ≥3 in women), regardless of the pattern or frequency of AF episodes 1, 2
The European Heart Journal suggests considering anticoagulation based on individual risk factors that favor treatment, even for patients with a CHA₂DS₂-VASc score of 1 (men) or 2 (women) 3, 1

Men with a CHA₂DS₂-VASc score ≥2 or women with a score ≥3 should receive oral anticoagulation, with options including NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or warfarin (INR 2.0-3.0) 1, 2
The American College of Cardiology recommends using the CHA₂DS₂-VASc score for risk assessment, with a score of 0 in men or 1 in women indicating low risk and no need for anticoagulation 1, 2
The European Heart Journal suggests that NOACs are preferred over warfarin due to lower intracranial hemorrhage rates and similar or superior efficacy 3

A single brief episode of AF due to a clearly reversible cause (e.g., acute myocardial infarction, thyrotoxicosis, acute alcohol intoxication) may not require long-term anticoagulation, but regular screening for AF recurrence is essential 3, 4
The American Heart Association recommends reassessing patients annually for new risk factors or AF recurrence, and starting anticoagulation if the patient meets criteria based on CHA₂DS₂-VASc score 1, 2

Age >65 years, type 2 diabetes mellitus, persistent or permanent AF pattern, and obesity are factors that support starting anticoagulation in borderline cases (CHA₂DS₂-VASc score of 1 in men or 2 in women) 3, 2

The American College of Cardiology recommends that anticoagulation decisions should be based on stroke risk factors, not on whether the AF episode was triggered by a reversible cause, with a high level of evidence 5
The European Society of Cardiology suggests calculating the patient's baseline thromboembolic risk using the CHA₂DS₂-VASc scoring system, which is a strong recommendation 6, 7
For patients with a CHA₂DS₂-VASc score ≥2, anticoagulation is recommended regardless of AF pattern, with a high level of evidence 6, 8

The American Heart Association recommends performing rhythm monitoring to detect AF recurrence after infection resolution, with a moderate level of evidence 9
If AF recurs after infection resolves, continue lifelong anticoagulation based on CHA₂DS₂-VASc score, with a high level of evidence 5

The European Heart Rhythm Association suggests using the HAS-BLED score to assess bleeding risk, but a high bleeding risk should prompt correction of modifiable factors, not avoidance of anticoagulation, with a moderate level of evidence 9
For patients with nonvalvular AF and CHA₂DS₂-VASc ≥2, first-line anticoagulation options include apixaban, rivaroxaban, or edoxaban, with a high level of evidence 6, 7